213 related articles for article (PubMed ID: 7673423)
1. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
Casslén B; Nordengren J; Gustavsson B; Nilbert M; Lund LR
J Clin Endocrinol Metab; 1995 Sep; 80(9):2776-84. PubMed ID: 7673423
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
Chung HW; Wen Y; Ahn JJ; Moon HS; Polan ML
J Clin Endocrinol Metab; 2001 Mar; 86(3):1332-40. PubMed ID: 11238529
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1.
Casslén B; Sandberg T; Gustavsson B; Willén R; Nilbert M
Biol Reprod; 1998 Jun; 58(6):1343-50. PubMed ID: 9623591
[TBL] [Abstract][Full Text] [Related]
4. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
5. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
7. Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.
Casslén B; Gustavsson B; Angelin B; Gåfvels M
Mol Hum Reprod; 1998 Jun; 4(6):585-93. PubMed ID: 9665342
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro expression of the plasminogen activators and urokinase type plasminogen activator receptor (u-PAR) in the pig oviduct.
Roldán-Olarte M; García DC; Jiménez-Díaz M; Valdecantos PA; Miceli DC
Anim Reprod Sci; 2012 Dec; 136(1-2):90-9. PubMed ID: 23103014
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of the influence of ovarian steroids on plasminogen activators and inhibitors in human endometrial cells and trophoblasts.
Ueyama M; Kasatori N; Urayama T; Maemura T; Yao Y; Shiraishi T; Saito S; Kubo H
Thromb Res; 2002 Nov; 108(4):235-44. PubMed ID: 12617987
[TBL] [Abstract][Full Text] [Related]
10. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
11. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
[TBL] [Abstract][Full Text] [Related]
12. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
13. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
19. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
